ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1036

The Independent Impact Of Depression On Incident Myocardial Infarction In Psoriatic Disease: A Population-Based Cohort Study

Lindsay C Burns1,2, Jan P. Dutz1 and Hyon Choi3,4,5, 1Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, 2Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 5Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, depression, Epidemiologic methods, population studies and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Psoriasis (PsC) and psoriatic arthritis (PsA) represent common, lifelong inflammatory diseases of the skin and joints (respectively) that are associated with substantial cardiovascular and psychiatric morbidity.  Considering that depression is associated with deleterious cardiovascular outcomes, we investigated the potential long-term impact of depression on myocardial infarction (MI) risk in this patient population. 

Methods: Our analysis employed linked administrative health data, including physician visits, hospital admissions, and death records from Apr 1991 to Mar 2006, and all dispensed medications from Apr 1996 to Mar 2006, for the entire adult (≥18 years) population of British Columbia, Canada (4.1 million individuals).  Inclusion in our incident PsC/PsA exposure cohort required one of the following: 1) ≥2 ICD-9 physician diagnostic codes specific for PsC/PsA within a 2 year period between Apr 1996 and Mar 2006; 2) ≥1 specific ICD-9 diagnostic code from a dermatologist (for PsC), a rheumatologist (for PsA), or from hospital.  Five unexposed, general population controls were matched to each PsC/PsA case by age, sex, and follow-up time (index date).  Individuals with diagnoses of PsC, PsA, or MI prior to the baseline were excluded.  Depression was defined by physician or hospital diagnosis, and MI was defined by hospitalization or death certificate.  We used Cox proportional hazards models to estimate the independent impact and potential effect modification of depression in psoriatic disease compared to matched controls, adjusting for age, sex, comorbidities, health resource utilization, and socioeconomic status. 

Results: Among 10,041 cases of incident PsC/PsA (51% male, mean age of 49 years), 268 incident MI events occurred (incidence = 5.8 per 1,000 person-years [PY]).  The incidence of depression in PsC/PsA was 3.4 per 1,000 PY and the corresponding 10-year prevalence estimate was 21.6%.  Individuals with PsC/PsA were more likely to be depressed (adjusted OR, 1.26) than controls.  Incident depression increased the risk of incident MI by 80% in PsC and PsA (adjusted RR, 1.8; 95% CI, 1.3-2.5).  Further, depression was found to modify the risk of MI in psoriatic conditions such that an increased risk was only observed among psoriatic individuals with depression (RRs = 1.6, P<0.01 vs. 1.1, ns). 

Conclusion: These population-based data suggest that depression is a prevalent and independent risk factor for MI among patients with PsC and PsA.  Moreover, our findings suggest that depression acted as a major effect modifier in the context of PsC and PsA, such that PsC and PsA only led to an increased risk of MI among individuals with depression.  These data underscore the need to actively screen for depression among PsC and PsA patients and closely monitor cardiovascular health in this high-risk group to improve long-term survival.

 

Main Effects of PsC/PsA and Incident Depression on Risk of MI

Parameter

RR (95% CI)*

PsC/PsA cohort (ref, matched controls)

1.14 (0.97-1.34)

Incident depression

1.80 (1.29-2.51)

 

 

Effect of PsC/PsA on Risk of MI According to Prevalent Depression Strata

Parameter

RR (95% CI)*

PsC/PsA cohort (ref, matched controls)

     With depression

     Without depression

1.58 (1.24-2.03)

1.14 (0.97-1.35)

*All RRs adjusted for age, sex, Charlson Comorbidity Index, socioeconomic status, history of hospitalizations, chronic obstructive pulmonary disease, obesity, alcoholism, liver disease, cerebrovascular accidents, hypertension, sepsis, varicose veins, peripheral vascular disease, congestive heart failure, chronic renal disease, inflammatory bowel disease, malignant neoplasms, trauma, and fractures, assessed in the year prior to the index date

 


Disclosure:

L. C. Burns,
None;

J. P. Dutz,
None;

H. Choi,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-independent-impact-of-depression-on-incident-myocardial-infarction-in-psoriatic-disease-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology